Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

Konstantinidou, P., Szydlo, R.M., Chase, A. & Goldman, J.M. Cytogenetic status pre-transplant as a predictor of outcome post bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant 25, 143–146 (2000).

McGlave, P. Unrelated donor transplant therapy for chronic myelogenous leukemia. Hematol. Oncol. Clin. North Am. 12, 93–105 (1998).

Collins, R.H., Jr. et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15, 433–444 (1997).

Kolb, H.J. et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86, 2041–2050 (1995).

van Rhee, F., Lin, F., Cullis, J.O. & Goldman, J. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor lymphocyte transfusions before the onset of hematological relapse. Blood 83, 3377–3383 (1994).

Faderl, S., Talpaz, M., Estrov, Z. & Kantarjian, H.M. Chronic myelogenous leukemia: biology and therapy. Ann. Intern. Med. 131, 207–219 (1999).

Dowding, C., Guo, A.P., Maisin, D., Gordon, M.Y. & Goldman, J.M. The effects of interferon-alpha on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint. Br. J. Haematol. 77, 165–171 (1991).

Gordon, M.Y. et al. Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. J. Clin. Invest. 102, 710–715 (1998).

den Haan, J.M. et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279, 1054–1057 (1998).

den Haan, J.M.M. et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268, 1476–1480 (1995).

Marijt, W.A. et al. Minor histocompatibility antigens HA-1, -2, and -4, and HY-specific cytotoxic T-cell clones inhibit human hematopoietic progenitor cell growth by a mechanism that is dependent on direct cell-cell contact. Blood 82, 3778–3785 (1995).

Goulmy, E. et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N. Engl. J. Med. 334, 281–285 (1996).

Falkenburg, J.H. et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 94, 1201–1208 (1999).

Childs, R., Epperson, D., Bahceci, E., Clave, E. & Barrett, J. Molecular remission of chronic myeloid leukaemia following a non- myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect. Br. J. Haematol. 107, 396–400 (1999).

Dengler, R. et al. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br. J. Haematol. 89, 250–257 (1995).

Bories, D., Raynal, M.C., Solomon, D.H., Darzynkiewicz, Z. & Cayre, Y.E. Down-regulation of a serine protease, myeloblastin, causes gwoth arrest and differentiation of promyelocytic leukemia cells. Cell 59, 959 (1989).

Molldrem, J. et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88, 2450–2457 (1996).

Molldrem, J.J. et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90, 2529–2534 (1997).

Molldrem, J.J., Lee, P.P., Wang, C., Champlin, R.E. & Davis, M.M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low- frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59, 2675–2681 (1999).

Altman, J.D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94–96 (1996).

Lee, P.P. et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Med. 5, 677–685 (1999).

Greiner, J.W. et al. Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha- interferon treatment. Cancer Res. 44, 3208–3214 (1984).

Natali, P.G. et al. Molecular profile, tissue distribution and prognostic evaluation of a human melanoma-carcinoma antigen recognized by the murine monoclonal antibody B1.1. Int. J. Biol. Markers 3, 211–220 (1988).

Dermime, S. et al. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant 19, 989–999 (1997).

Faber, L.M. et al. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J. Clin. Invest. 96, 877–883 (1995).

McLaughlin-Taylor, E. et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J. Med. Virol. 43, 103–110 (1994).

Riddell, S.R. & Greenberg, P.D. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13, 545–586 (1995).

Salter, R.D. & Cresswell, P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. Embo. J. 5, 943–949 (1986).

Anderson, K. et al. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I- restricted cell-mediated lysis. J. Exp. Med. 174, 489–492 (1991).